COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Phase 3, Multicenter Study Designed To Evaluate The Efficacy And Safety Of A Long Acting Hgh Product (Mod-4023) In Adult Subjects With Growth Hormone Deficiency

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01909479
Recruitment Status : Terminated (Main Study was completed. LT-OLE was discontinued as sufficient safety data has been generated.)
First Posted : July 26, 2013
Last Update Posted : December 13, 2019
Information provided by (Responsible Party):
OPKO Health, Inc.

Brief Summary:
This will be a randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adult subjects with GHD to assess the safety and efficacy of a long-acting, once weekly injection of modified hGH (MOD-4023).

Condition or disease Intervention/treatment Phase
Adult Growth Hormone Deficiency Drug: MOD-4023 Other: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 189 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Study Start Date : June 2013
Actual Primary Completion Date : August 2016
Actual Study Completion Date : August 2018

Arm Intervention/treatment
Experimental: MOD-4023 Drug: MOD-4023
Individualized once weekly dose of MOD-4023

Placebo Comparator: Placebo Other: Placebo
Once weekly administration of placebo

Primary Outcome Measures :
  1. Change in trunk FM, expressed in kilograms measured with DXA, from baseline to week 26 [ Time Frame: 26 weeks ]
  2. Safety measures [ Time Frame: 52 weeks ]
    AEs, abnormal laboratory results (including glucose metabolism), immunogenicity, ECG.

Secondary Outcome Measures :
  1. Change in total FM, expressed in kilograms, measured with DXA, from baseline to 26 and 52 weeks [ Time Frame: 52 weeks ]
  2. Change in lean body mass, expressed in kilograms measured with DXA, from baseline to 26 and 52 weeks [ Time Frame: 52 weeks ]
  3. Change in trunk FM, expressed in kilograms measured with DXA, from baseline to 52 weeks [ Time Frame: 52 weeks ]
  4. Change in trunk FM, expressed as % change from baseline, measured with DXA, from baseline to 26 and 52 weeks [ Time Frame: 52 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   23 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women between the age of 23 to 70 years old at screening, inclusive
  • GHD subjects as defined in the Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II (2007).
  • No r-hGH replacement therapy or use of GH secretagogues for at least 9 months with any registered or investigational r-hGH or GH secretagogue product.
  • The IGF-I level at screening ≤-1 SDS of the age and sex normal ranges according to the central laboratory measurements
  • Subjects who are on a stable diet and exercise regime and do not have plans to modify their diet or exercise for at least 12 months
  • Subject had a DXA screening and the results are interpretable according to the study plan.

Exclusion Criteria:

  • Women who are pregnant or breast-feeding (at least 6 months delay from childbirth or lactation)
  • Evidence of growth benign intracranial tumor within the last 12 months (determined by comparing a previous MRI to a new one obtained no more than 6 months prior to study entry to clarify dynamics of growth).
  • History of any cancer. Exceptions to this exclusion criterion include resected in situ carcinoma of the cervix and squamous cell or basal cell carcinoma of the skin with complete local excision. Patients with GHD attributed to treatment of intracranial malignant lesions in childhood or adulthood (or, tumors) or leukemia may also be enrolled into the study provided that a recurrence-free survival period of at least 5 years is well documented in the study record.
  • Signs of intracranial hypertension at screening
  • Heart insufficiency, NYHA class > 2 (Appendix B)
  • History of overt diabetes mellitus (including currently treated, well-controlled DM) defined according to the American Diabetes Association (ADA) Criteriaa. A history of gestational diabetes, resolved after childbirth, is not exclusionary.
  • History of Acromegaly

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01909479

Layout table for location information
Opko Biologics
Kiryat Gat, Israel, 8211804
Sponsors and Collaborators
OPKO Health, Inc.
Layout table for additonal information
Responsible Party: OPKO Health, Inc. Identifier: NCT01909479    
Other Study ID Numbers: CP-4-005
2013-000830-37 ( EudraCT Number )
First Posted: July 26, 2013    Key Record Dates
Last Update Posted: December 13, 2019
Last Verified: December 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Dwarfism, Pituitary
Endocrine System Diseases
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Bone Diseases, Endocrine
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases